Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations

References

• Sung H , FerlayJ, SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Antoni S , FerlayJ, SoerjomataramI, ZnaorA, JemalA, BrayF. Bladder cancer incidence and mortality: a global overview and recent trends. Eur. Urol.71(1), 96–108 (2017).
   PubMed Web of Science ®Google Scholar
• Cumberbatch MGK , JubberI, BlackPCet al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur. Urol.74(6), 784–795 (2018).
   PubMed Web of Science ®Google Scholar
• Nadal R , BellmuntJ. Management of metastatic bladder cancer. Cancer Treat. Rev.76, 10–21 (2019).
   PubMed Web of Science ®Google Scholar
• von der Maase H , HansenSW, RobertsJTet al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. JCO18(17), 3068–3077 (2000).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer v1.22 (2022). www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
   Google Scholar
• Kaufman D , RaghavanD, CarducciMet al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. JCO18(9), 1921–1927 (2000).
   PubMed Web of Science ®Google Scholar
• Necchi A , PondGR, RaggiDet al. Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first-line setting of metastatic urothelial carcinoma: a systematic review and meta-analysis. Clin. Genitour. Cancer15(1), 23–30.e2 (2017).
   PubMed Web of Science ®Google Scholar
• Fradet Y , BellmuntJ, VaughnDJet al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann. Oncol.30(6), 970–976 (2019).
   PubMed Web of Science ®Google Scholar
• Rosenberg JE , Hoffman-CensitsJ, PowlesTet al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet387(10031), 1909–1920 (2016).
   PubMed Web of Science ®Google Scholar
• Powles T , vander Heijden MS, CastellanoDet al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol.21(12), 1574–1588 (2020).
   PubMed Web of Science ®Google Scholar
• Sharma P , Siefker-RadtkeA, de BraudFet al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results. JCO37(19), 1608–1616 (2019).
   PubMed Web of Science ®Google Scholar
• Balar AV , GalskyMD, RosenbergJEet al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet389(10064), 67–76 (2017).
   PubMed Web of Science ®Google Scholar
• Balar AV , CastellanoD, O'DonnellPHet al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol.18(11), 1483–1492 (2017).
   PubMed Web of Science ®Google Scholar
• Powles T , RosenbergJE, SonpavdeGPet al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N. Engl. J. Med.384(12), 1125–1135 (2021).
   PubMed Web of Science ®Google Scholar
• Roskoski R . The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol. Res.151, 104567 (2020).
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network . Comprehensive molecular characterization of urothelial bladder carcinoma. Nature507(7492), 315–322 (2014).
   PubMed Web of Science ®Google Scholar
• Robertson AG , KimJ, Al-AhmadieHet al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell171(3), 540–556.e25 (2017).
   PubMed Web of Science ®Google Scholar
• Nassar AH , UmetonR, KimJet al. Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites. Clin. Cancer Res.25(8), 2458–2470 (2019).
   PubMed Web of Science ®Google Scholar
• Babina IS , TurnerNC. Advances and challenges in targeting FGFR signaling in cancer. Nat. Rev. Cancer17(5), 318–332 (2017).
   PubMed Web of Science ®Google Scholar
• Morales-Barrera R , SuárezC, de CastroAMet al. Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: new direction and new hope. Cancer Treat. Rev.50, 208–216 (2016).
   PubMed Web of Science ®Google Scholar
• Milowsky MI , DittrichC, DuránIet al. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur. J. Cancer50(18), 3145–3152 (2014).
   PubMed Web of Science ®Google Scholar
• Mazzola CR , SiddiquiKM, BilliaM, ChinJ. Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder. Exp. Opin. Investig. Drugs23(11), 1553–1562 (2014).
   PubMed Web of Science ®Google Scholar
• Hoy SM . Pemigatinib: first approval. Drugs80(9), 923–929 (2020).
   PubMed Web of Science ®Google Scholar
• Pal SK , RosenbergJE, Hoffman-CensitsJHet al. Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov.8(7), 812–821 (2018).
   PubMed Web of Science ®Google Scholar
• Siefker-Radtke AO , CurrieG, AbellaEet al. FIERCE-22: clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. JCO37(Suppl. 15), 4511–4511 (2019).
   Google Scholar
• Casadei C , DizmanN, SchepisiGet al. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Ther. Adv. Med. Oncol.11, 175883591989028 (2019).
   Web of Science ®Google Scholar
• Scholtes MP , AlbertsAR, IfléIG, VerhagenPCMS, vander Veldt AAM, ZuiverloonTCM. Biomarker-oriented therapy in bladder and renal cancer. IJMS22(6), 2832 (2021).
   Google Scholar
• Marandino L , RaggiD, GiannatempoP, FarèE, NecchiA. Erdafitinib for the treatment of urothelial cancer. Exp. Rev. Anticancer Ther.19(10), 835–846 (2019).
   PubMed Web of Science ®Google Scholar
• Perera TPS , JovchevaE, MevellecLet al. Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol. Cancer Ther.16(6), 1010–1020 (2017).
   PubMed Web of Science ®Google Scholar
• Roskoski R . Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol. Res.152, 104609 (2020).
   PubMed Web of Science ®Google Scholar
• Bahleda R , ItalianoA, HierroCet al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin. Cancer Res.25(16), 4888–4897 (2019).
   PubMed Web of Science ®Google Scholar
• Li LY , GuoY, GonzalezM, OuelletD. Effect of plasma protein binding on the pharmacokinetics of erdafitinib: results of an integrated cross-study analysis. J. Clin. Pharmacol.60(3), 391–399 (2020).
   PubMed Web of Science ®Google Scholar
• Dosne A , ValadeE, StuyckensK, LiLY, OuelletD, Perez-RuixoJJ. Population pharmacokinetics of total and free erdafitinib in adult healthy volunteers and cancer patients: analysis of phase 1 and phase 2 studies. J. Clin. Pharmacol.60(4), 515–527 (2020).
   PubMed Web of Science ®Google Scholar
• Nauseef JT , VillamarDM, LebenthalJ, VlachostergiosPJ, TagawaST. An evaluation of the efficacy and safety of Erdafitinib for the treatment of bladder cancer. Exp. Opin. Pharmacother.21(8), 863–870 (2020).
   PubMed Web of Science ®Google Scholar
• Tabernero J , BahledaR, DienstmannRet al. Phase I dose-escalation study of JNJ-42756493, an oral pan–fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. JCO33(30), 3401–3408 (2015).
   PubMed Web of Science ®Google Scholar
• FDA.gov . FDA approves first targeted therapy for metastatic bladder cancer (2019). www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-Erdafitinib-metastatic-urothelial-carcinoma
   Google Scholar
• Loriot Y , NecchiA, ParkSHet al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl. J. Med.381(4), 338–348 (2019).
   PubMed Web of Science ®Google Scholar
• Kommalapati A , TellaSH, BoradM, JavleM, MahipalA. FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice. Cancers13(12), 2968 (2021).
   PubMed Web of Science ®Google Scholar
• Roubal K , MyintZW, KolesarJM. Erdafitinib: a novel therapy for FGFR-mutated urothelial cancer. Am. J. Health Syst. Pharm.77(5), 346–351 (2020).
   PubMed Web of Science ®Google Scholar
• Lu X , HuMC. Klotho/FGF23 axis in chronic kidney disease and cardiovascular disease. Kidney Dis.3(1), 15–23 (2017).
   Web of Science ®Google Scholar
• Brauer A , WaheedS, SinghT, MaursetterL. Improvement in hyperphosphatemia using phosphate education and planning talks. J. Ren. Nutri.29(2), 156–162 (2019).
   PubMed Web of Science ®Google Scholar
• Joshi S , PotluriV, ShahS. Dietary management of hyperphosphatemia. Am. J. Kidney Dis.72(1), 155–156 (2018).
   PubMed Web of Science ®Google Scholar
• Moe SM , ZidehsaraiMP, ChambersMAet al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. CJASN6(2), 257–264 (2011).
   PubMed Web of Science ®Google Scholar
• Ghimire S , CastelinoRL, LioufasNM, PetersonGM, ZaidiSTR. Nonadherence to medication therapy in haemodialysis patients: a systematic review. PLoS ONE10(12), e0144119 (2015).
   PubMed Web of Science ®Google Scholar
• Navarro-González JF , Sánchez-NiñoMD, Donate-CorreaJet al. Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease. Dia. Care41(8), 1817–1820 (2018).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A Study of erdafitinib compared with vinflunine or docetaxel or pembrolizumab in participants with advanced urothelial cancer and selected fibroblast growth factor receptor (FGFR) gene aberrations (2022). https://clinicaltrials.gov/ct2/show/NCT03390504
   Google Scholar
• Moreno V , LoriotY, ValderramaBPet al. Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations. JCO38(Suppl. 6), 511–511 (2020).
   Web of Science ®Google Scholar
• ClinicalTrials.gov . A study of erdafitinib in participants with metastatic or locally advanced urothelial cancer (2022). https://clinicaltrials.gov/ct2/show/NCT03473743
   Google Scholar